Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Guideline

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho

Clin Mol Hepatol. 2021;27(3):363-401. Published online June 22, 2021

Web of Science 138 Crossref 148

DOI: https://doi.org/10.3350/cmh.2021.0178

Reviews

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim

Clin Mol Hepatol. 2021;27(3):402-412. Published online June 23, 2021

Web of Science 32 Crossref 30

DOI: https://doi.org/10.3350/cmh.2021.0179

Anti-fibrotic treatments for chronic liver diseases: The present and the future

Naoshi Odagiri, Tsutomu Matsubara, Misako Sato-Matsubara, Hideki Fujii, Masaru Enomoto, Norifumi Kawada

Clin Mol Hepatol. 2021;27(3):413-424. Published online December 3, 2020

Web of Science 25 Crossref 24

DOI: https://doi.org/10.3350/cmh.2020.0187

β-blockers in advanced cirrhosis: More friend than enemy

Ki Tae Yoon, Hongqun Liu, Samuel S. Lee

Clin Mol Hepatol. 2021;27(3):425-436. Published online December 3, 2020

Web of Science 22 Crossref 24

DOI: https://doi.org/10.3350/cmh.2020.0234

Changes in the epidemiology and management of bacterial infections in cirrhosis

Salvatore Piano, Marta Tonon, Paolo Angeli

Clin Mol Hepatol. 2021;27(3):437-445. Published online January 28, 2021

Web of Science 26 Crossref 29

DOI: https://doi.org/10.3350/cmh.2020.0329

Editorials

An analysis of polygenic risk scores for non-alcoholic fatty liver disease

Dae Won Jun

Clin Mol Hepatol. 2021;27(3):446-447. Published online May 21, 2021

Web of Science 5 Crossref 5

DOI: https://doi.org/10.3350/cmh.2021.0133

Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2021;27(3):448-450. Published online June 23, 2021

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2021.0130

Original Articles

Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry

Jong Man Kim, Deok Gie Kim, Jihyun Kim, Keunsung Lee, Kwang-Woong Lee, Je Ho Ryu, Bong-Wan Kim, Dong Lak Choi, Young Kyoung You, Dong-Sik Kim, Yang Won Nah, Koo Jeong Kang, Jai Young Cho, Geun Hong, Hee Chul Yu, Ju Ik Moon, Dongho Choi, Shin Hwang, Myoung Soo Kim

Clin Mol Hepatol. 2021;27(3):451-462. Published online February 2, 2021

Web of Science 31 Crossref 33

DOI: https://doi.org/10.3350/cmh.2020.0292

Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome

Han Ah Lee, Jihwan Lim, Hyung Joon Joo, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Do-Sun Lim, Kwan Soo Byun, Yeon Seok Seo

Clin Mol Hepatol. 2021;27(3):463-473. Published online February 15, 2021

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2020.0351

The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients

Yu Jun Wong, Prem Harichander Thurairajah, Rahul Kumar, Kwong Ming Fock, Ngai Moh Law, Sin-Yoong Chong, Fria Gloriba Manejero, Tiing-Leong Ang, Eng Kiong Teo, Jessica Tan

Clin Mol Hepatol. 2021;27(3):474-485. Published online February 19, 2021

Web of Science 8 Crossref 8

DOI: https://doi.org/10.3350/cmh.2021.0015

Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort

Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, Wah-Kheong Chan, Hwa-Li Tan, Zahurin Mohamed, Yuh-Fen Pung, Rosmawati Mohamed

Clin Mol Hepatol. 2021;27(3):486-498. Published online February 23, 2021

Web of Science 18 Crossref 21

DOI: https://doi.org/10.3350/cmh.2020.0162

Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B

Lilian Yan Liang, Hye Won Lee, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vicki Wing-Ki Hui, Grace Chung-Yan Lui, Henry Lik-Yuen Chan, Grace Lai-Hung Wong

Clin Mol Hepatol. 2021;27(3):499-509. Published online February 26, 2021

Web of Science 14 Crossref 14

DOI: https://doi.org/10.3350/cmh.2020.0333

Letter to the Editor

The major diagnostic role of autoantibodies in the diagnosis of autoimmune hepatitis, a disease of all ages

Linda Beenet

Clin Mol Hepatol. 2021;27(3):510-511. Published online March 22, 2021

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2021.0058

Snapshot

Hepatocellular carcinoma statistics in South Korea

Young Eun Chon, Soung Won Jeong, Dae Won Jun

Clin Mol Hepatol. 2021;27(3):512-514. Published online June 21, 2021

Web of Science 24 Crossref 24

DOI: https://doi.org/10.3350/cmh.2021.0171

Viewed By 5133	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4993	MAFLD: How is it different from NAFLD?
Viewed By 4889	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3594	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3564	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 67	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 51	MAFLD: How is it different from NAFLD?

Previous issues